MLYS - CIK 0001933414
The table below shows Mineralys Therapeutics, Inc.'s cash flow statement line items across its last 4 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating cash flow | -$142.42M | -$166.31M | -$81.17M | -$29.22M |
| Capital expenditure | - | - | - | - |
| Investing cash flow | -$389.75M | $114.96M | -$160.47M | -$21.76M |
| Dividends paid | - | - | - | - |
| Stock buybacks | - | - | - | - |
| Financing cash flow | $591.00M | $116.14M |
Mineralys Therapeutics, Inc. reported operating cash flow of -$142.42M for fiscal year 2025. That is up 14.4% from -$166.31M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $203.25M |
| $128.02M |